What are my alternatives to knee replacement?
Compare nonsurgical knee arthritis care, injection choices, and selected surgical alternatives—with evidence, limits, and questions for your clinician.
Read the guide ↗Medically reviewed by Charles A. DeCook, MD ·
← All optionsLearn about the evidence
Arthrosamid hydrogel
A watch-list item. No US checkout here.
Who might it suit?
For: Understanding a polyacrylamide hydrogel offered elsewhere.
Not for: A US commercial treatment through this site.
Limits and important cautions
The trial had no placebo group and more mild/moderate device-related adverse effects with hydrogel. It does not prove cartilage regrowth or superiority to established care. US approval remains unverified here.
What happens, how long, and what could it cost?
- What happens
- Ask the clinician to explain the exact product or procedure and confirm the diagnosis before treatment.
- When might I notice a change?
- A reliable personal timeline cannot be predicted from the evidence reviewed here. Agree on a review date before starting.
- How long might benefit last?
- Benefit and durability depend on the exact intervention and population. The evidence section below explains what is known.
- Repeat treatment
- Agree on a review date and criteria for continuing, changing, or stopping.
- Activity and recovery
- Ask who provides follow-up, what symptoms need urgent attention, and what restrictions apply to you.
- Ask for a complete estimate
- Consultation, exact product or procedure, any tests, follow-up, and repeat treatment.
Use this as a consultation guide. A timeline is not a guarantee; the evidence and FDA sections below remain part of the decision.
THE EVIDENCE IN CONTEXT
Active-comparator evidence; placebo benefit uncertain
Read the 2 selected references
- Bliddal et al.: polyacrylamide hydrogel versus HA ↗
239 participants; met the 26-week noninferiority criterion against HA. No placebo arm; more mild/moderate device-related adverse effects occurred with hydrogel.
- Polyacrylamide hydrogel: five-year extension ↗
Reports sustained improvement among follow-up participants. Only 58 of the original 119 treated participants completed five years; no concurrent placebo comparison.
FDA status
US approval: UNSUREUS approval has not been established in this catalog. No US SKU is offered.
Site summary of FDA information · reviewed September 19, 2026. Refer to current product labeling. This is not an FDA endorsement of this site.What do professional guidelines say?
ACR: No recommendation for this product.
Will Medicare cover it?
No established coverage in this catalog.